Vobramitamab

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb) . Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma[1][2][3][4].

Product Specifications

CAS Number

[2490556-50-6]

Product Name Alternative

AEX-4089; MGC026 antibody

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vobramitamab.html

Purity

99.67

Solubility

10 mM in DMSO|H2O

Smiles

[Vobramitamab]

Molecular Weight

(144.691 kDa)

References & Citations

[1]Brignole C, et al. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models[J]. Cancer Research, 2023, 83 (7_Supplement) : 2981-2981.|[2]Brignole C, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023 Sep;11 (9) :e007174.|[3]Danielle C Kirkey MD, et al. CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate. Blood.Volume 142, Supplement 1, 2 November 2023, Page 5958|[4]Scribner JA, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19 (11) :2235-2244.